25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

TKD (Takeda) Stock Analysis
Buy, Hold or Sell?

Let's analyze Takeda together

I guess you are interested in Takeda Pharmaceutical Company Limited. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • πŸ“Š Fundamental Analysis (FA) – Takeda’s Financial Insights
  • πŸ“ˆ Technical Analysis (TA) – Takeda’s Price Targets

I'm going to help you getting a better view of Takeda Pharmaceutical Company Limited. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Takeda Pharmaceutical Company Limited

I send you an email if I find something interesting about Takeda Pharmaceutical Company Limited.

1. Quick Overview

1.1. Quick analysis of Takeda (30 sec.)










1.2. What can you expect buying and holding a share of Takeda? (30 sec.)

How much money do you get?

How much money do you get?
€1.32
When do you have the money?
1 year
How often do you get paid?
100.0%

What is your share worth?

Current worth
€28.08
Expected worth in 1 year
€30.38
How sure are you?
69.7%

+ What do you gain per year?

Total Gains per Share
€3.44
Return On Investment
13.4%

For what price can you sell your share?

Current Price per Share
€25.76
Expected price per share
€23.99 - €27.12
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Takeda (5 min.)




Live pricePrice per Share (EOD)
€25.76
Intrinsic Value Per Share
€18.04 - €20.92
Total Value Per Share
€46.12 - €49.01

2.2. Growth of Takeda (5 min.)




Is Takeda growing?

Current yearPrevious yearGrowGrow %
How rich?$51.1b$46.7b$4b7.9%

How much money is Takeda making?

Current yearPrevious yearGrowGrow %
Making money$358.8m$307.3m$51.4m14.3%
Net Profit Margin4.4%4.2%--

How much money comes from the company's main activities?

2.3. Financial Health of Takeda (5 min.)




3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Takeda?

Welcome investor! Takeda's management wants to use your money to grow the business. In return you get a share of Takeda.

First you should know what it really means to hold a share of Takeda. And how you can make/lose money.

Speculation

The Price per Share of Takeda is €25.76. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Takeda.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Takeda, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is €28.08. Based on the TTM, the Book Value Change Per Share is €0.57 per quarter. Based on the YOY, the Book Value Change Per Share is €0.51 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is €0.29 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Takeda.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 β‚¬% of Price per Share€% of Price per Share€% of Price per Share€% of Price per Share€% of Price per Share€% of Price per Share
Usd Eps0.100.4%0.230.9%0.040.2%0.190.7%0.251.0%0.150.6%
Usd Book Value Change Per Share2.178.4%0.662.6%0.592.3%0.732.8%0.542.1%0.983.8%
Usd Dividend Per Share0.632.5%0.331.3%0.180.7%0.271.1%0.291.1%0.190.8%
Usd Total Gains Per Share2.8010.9%0.993.8%0.783.0%1.003.9%0.833.2%1.174.6%
Usd Price Per Share28.47-28.92-32.48-30.74-31.74-36.52-
Price to Earnings Ratio68.75--113.24-0.24--44.92-56.71-166.29-
Price-to-Total Gains Ratio10.17-6.25-19.52-10.75-10.87--443.71-
Price to Book Ratio0.88-0.90-1.09-1.04-1.23-108.63-
Price-to-Total Gains Ratio10.17-6.25-19.52-10.75-10.87--443.71-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share29.618848
Number of shares33
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.330.29
Usd Book Value Change Per Share0.660.54
Usd Total Gains Per Share0.990.83
Gains per Quarter (33 shares)32.6727.27
Gains per Year (33 shares)130.70109.10
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
14487121387199
28717425276142208
3131261383114213317
4174349514153284426
5218436645191355535
6261523776229426644
7305610907267497753
83496971038305568862
93927841169343639971
1043687113003817101080

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share3.01.00.075.0%8.04.00.066.7%16.04.00.080.0%25.08.00.075.8%25.08.00.075.8%
Book Value Change Per Share3.01.00.075.0%9.03.00.075.0%13.07.00.065.0%20.013.00.060.6%20.013.00.060.6%
Dividend per Share4.00.00.0100.0%12.00.00.0100.0%20.00.00.0100.0%33.00.00.0100.0%33.00.00.0100.0%
Total Gains per Share3.01.00.075.0%9.03.00.075.0%15.05.00.075.0%23.010.00.069.7%23.010.00.069.7%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Takeda Pharmaceutical Company Limited compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share--1.8830.574+228%0.515+266%0.633+197%0.467+303%0.851+121%
Book Value Per Share--28.08227.980+0%25.958+8%25.948+8%23.209+21%14.682+91%
Current Ratio--1.3131.240+6%1.015+29%1.143+15%1.233+6%1.339-2%
Debt To Asset Ratio--0.5090.518-2%0.532-4%0.533-5%0.562-9%0.562-9%
Debt To Equity Ratio--1.0361.075-4%1.137-9%1.146-10%1.305-21%1.315-21%
Dividend Per Share--0.5510.287+92%0.160+245%0.238+131%0.251+119%0.169+226%
Enterprise Value---6876879794.760-7737706287.775+13%-1922637258.555-72%-4485522548.777-35%-2931218086.158-57%1657574223271.559-100%
Eps--0.0900.198-54%0.039+131%0.167-46%0.219-59%0.134-33%
Ev To Sales Ratio---0.250-0.280+12%-0.073-71%-0.173-31%-0.115-54%132.513-100%
Free Cash Flow Per Share--1.2380.724+71%-0.125+110%0.461+168%0.566+119%0.566+119%
Free Cash Flow To Equity Per Share---1.2450.246-607%-0.623-50%-0.167-87%-0.205-84%-0.205-84%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--20.924----------
Intrinsic Value_10Y_min--18.039----------
Intrinsic Value_1Y_max--1.885----------
Intrinsic Value_1Y_min--1.851----------
Intrinsic Value_3Y_max--5.824----------
Intrinsic Value_3Y_min--5.557----------
Intrinsic Value_5Y_max--9.959----------
Intrinsic Value_5Y_min--9.229----------
Market Cap40232998400.000+2%39249038205.24039665734712.225-1%44210390741.445-11%41916351951.223-6%43241842213.842-9%1695543374544.286-98%
Net Profit Margin--0.0210.044-52%0.042-50%0.051-59%0.071-71%0.062-67%
Operating Margin----0%0.058-100%0.058-100%0.090-100%0.112-100%
Operating Ratio--1.3841.235+12%1.261+10%1.238+12%1.202+15%1.211+14%
Pb Ratio0.917+4%0.8820.902-2%1.090-19%1.039-15%1.232-28%108.626-99%
Pe Ratio71.522+4%68.745-113.242+265%0.240+28559%-44.922+165%56.713+21%166.294-59%
Price Per Share25.760+4%24.76025.150-2%28.245-12%26.735-7%27.603-10%31.765-22%
Price To Free Cash Flow Ratio5.201+4%5.00017.675-72%3.858+30%-1.247+125%3.857+30%2.338+114%
Price To Total Gains Ratio10.583+4%10.1736.246+63%19.523-48%10.751-5%10.870-6%-443.709+4462%
Quick Ratio--0.3550.328+8%0.318+11%0.336+6%0.382-7%0.433-18%
Return On Assets--0.0020.003-54%0.003-50%0.004-59%0.005-68%0.005-70%
Return On Equity--0.0030.007-55%0.007-52%0.008-61%0.012-72%0.012-73%
Total Gains Per Share--2.4340.861+183%0.674+261%0.872+179%0.719+239%1.020+139%
Usd Book Value--51183514870.80050730368917.500+1%46722074708.400+10%46793922261.000+9%41824867359.780+22%33366190029.527+53%
Usd Book Value Change Per Share--2.1660.660+228%0.592+266%0.728+197%0.538+303%0.978+121%
Usd Book Value Per Share--32.28932.172+0%29.846+8%29.835+8%26.686+21%16.881+91%
Usd Dividend Per Share--0.6330.330+92%0.183+245%0.274+131%0.289+119%0.194+226%
Usd Enterprise Value---7907036388.015-8896814689.684+13%-2210648319.887-72%-5157453826.583-35%-3370314555.464-57%1905878841917.638-100%
Usd Eps--0.1040.227-54%0.045+131%0.192-46%0.252-59%0.154-33%
Usd Free Cash Flow--2256631974.0001314883684.800+72%-222546664.500+110%834159203.600+171%1021466682.720+121%619070716.800+265%
Usd Free Cash Flow Per Share--1.4240.832+71%-0.143+110%0.531+168%0.651+119%0.651+119%
Usd Free Cash Flow To Equity Per Share---1.4310.283-607%-0.716-50%-0.192-87%-0.236-84%-0.236-84%
Usd Market Cap46259901560.320+2%45128544128.38545607661772.116-1%50833107274.514-11%48195421473.517-6%49719470177.476-9%1949535772051.020-98%
Usd Price Per Share29.619+4%28.46928.917-2%32.476-12%30.740-7%31.738-10%36.524-22%
Usd Profit--164115553.200358849705.500-54%307374309.300-47%379899094.100-57%463133346.060-65%340814099.491-52%
Usd Revenue--7893082651.2007897437518.7000%7190358810.300+10%7297022306.900+8%6677318165.280+18%5566370576.255+42%
Usd Total Gains Per Share--2.7990.990+183%0.775+261%1.002+179%0.826+239%1.172+139%
 EOD+4 -4MRQTTM+23 -14YOY+21 -173Y+19 -195Y+18 -2010Y+19 -19

3.3 Fundamental Score

Let's check the fundamental score of Takeda Pharmaceutical Company Limited based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1571.522
Price to Book Ratio (EOD)Between0-10.917
Net Profit Margin (MRQ)Greater than00.021
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.355
Current Ratio (MRQ)Greater than11.313
Debt to Asset Ratio (MRQ)Less than10.509
Debt to Equity Ratio (MRQ)Less than11.036
Return on Equity (MRQ)Greater than0.150.003
Return on Assets (MRQ)Greater than0.050.002
Total4/10 (40.0%)

3.4 Technical Score

Let's check the technical score of Takeda Pharmaceutical Company Limited based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose25.760
Total0/1 (0.0%)

4. In-depth Analysis

4.1 About Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, ADZYNMA, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, FRUZAQLA, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, QDENGA, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.

Fundamental data was last updated by Penke on 2025-06-16 13:14:04.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a profit.
Using its assets, the company is inefficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is just able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is underpriced.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitΒ Takeda earns for each €1 of revenue.

  • Above 10% is considered healthy but always compareΒ Takeda to theΒ Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of 2.1%Β means thatΒ €0.02 for each €1Β in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Takeda Pharmaceutical Company Limited:

  • The MRQ is 2.1%. The company is making a profit. +1
  • The TTM is 4.4%. The company is making a profit. +1
Trends
Current periodCompared to+/- 
MRQ2.1%TTM4.4%-2.3%
TTM4.4%YOY4.2%+0.2%
TTM4.4%5Y7.1%-2.7%
5Y7.1%10Y6.2%+0.8%
4.3.1.2. Return on Assets

Shows howΒ efficientΒ Takeda is using its assets to generate profit.

  • Above 5% is considered healthyΒ but always compareΒ Takeda to theΒ Drug Manufacturers - Specialty & Generic industry mean.
  • 0.2% Return on Assets means thatΒ Takeda generatedΒ €0.00 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Takeda Pharmaceutical Company Limited:

  • The MRQ is 0.2%. Using its assets, the company is inefficient in making profit. -1
  • The TTM is 0.3%. Using its assets, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ0.2%TTM0.3%-0.2%
TTM0.3%YOY0.3%+0.0%
TTM0.3%5Y0.5%-0.2%
5Y0.5%10Y0.5%0.0%
4.3.1.3. Return on Equity

Shows how efficient Takeda is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareΒ Takeda to theΒ Drug Manufacturers - Specialty & Generic industry mean.
  • 0.3% Return on Equity means Takeda generated €0.00Β for eachΒ €1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Takeda Pharmaceutical Company Limited:

  • The MRQ is 0.3%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is 0.7%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ0.3%TTM0.7%-0.4%
TTM0.7%YOY0.7%+0.0%
TTM0.7%5Y1.2%-0.5%
5Y1.2%10Y1.2%0.0%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Takeda Pharmaceutical Company Limited.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

MeasuresΒ how efficient Takeda is operatingΒ .

  • Measures how much profit Takeda makes for each €1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareΒ Takeda to theΒ Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 0.0%Β means the company generated €0.00 Β for each €1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Takeda Pharmaceutical Company Limited:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY5.8%-5.8%
TTM-5Y9.0%-9.0%
5Y9.0%10Y11.2%-2.1%
4.3.2.2. Operating Ratio

Measures how efficient Takeda is keepingΒ operating costsΒ low.

  • Below 1 is considered healthy (always compare toΒ Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 1.38 means that the operating costs are €1.38 for each €1 in net sales.

Let's take a look of the Operating Ratio trends of Takeda Pharmaceutical Company Limited:

  • The MRQ is 1.384. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.235. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.384TTM1.235+0.149
TTM1.235YOY1.261-0.026
TTM1.2355Y1.202+0.033
5Y1.20210Y1.211-0.009
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Takeda Pharmaceutical Company Limited.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Takeda is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toΒ Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 1.31Β means the company has €1.31 in assets for each €1 in short-term debts.

Let's take a look of the Current Ratio trends of Takeda Pharmaceutical Company Limited:

  • The MRQ is 1.313. The company is just able to pay all its short-term debts.
  • The TTM is 1.240. The company is just able to pay all its short-term debts.
Trends
Current periodCompared to+/- 
MRQ1.313TTM1.240+0.073
TTM1.240YOY1.015+0.225
TTM1.2405Y1.233+0.007
5Y1.23310Y1.339-0.106
4.4.3.2. Quick Ratio

Measures if Takeda is able to pay off Short-term Debt but only usingΒ theΒ most liquid assets.

  • Above 1 is considered healthy butΒ always compareΒ Takeda to theΒ Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 0.35Β means the company can pay off €0.35 for each €1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Takeda Pharmaceutical Company Limited:

  • The MRQ is 0.355. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.328. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.355TTM0.328+0.026
TTM0.328YOY0.318+0.010
TTM0.3285Y0.382-0.054
5Y0.38210Y0.433-0.051
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Takeda Pharmaceutical Company Limited.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %Β of TakedaΒ assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareΒ Takeda to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.51Β means that Takeda assets areΒ financed with 50.9% credit (debt) and the remaining percentage (100% - 50.9%)Β is financed by its owners/shareholders.Β 

Let's take a look of the Debt to Asset Ratio trends of Takeda Pharmaceutical Company Limited:

  • The MRQ is 0.509. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.518. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.509TTM0.518-0.009
TTM0.518YOY0.532-0.014
TTM0.5185Y0.562-0.044
5Y0.56210Y0.562+0.001
4.5.4.2. Debt to Equity Ratio

Measures ifΒ Takeda is able toΒ pay off its debts by usingΒ shareholders equity.

  • Below 2 is considered healthy butΒ always compareΒ Takeda to theΒ Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 103.6% means that company has €1.04 debt for each €1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Takeda Pharmaceutical Company Limited:

  • The MRQ is 1.036. The company is able to pay all its debts with equity. +1
  • The TTM is 1.075. The company is able to pay all its debts with equity. +1
Trends
Current periodCompared to+/- 
MRQ1.036TTM1.075-0.039
TTM1.075YOY1.137-0.062
TTM1.0755Y1.305-0.230
5Y1.30510Y1.315-0.010
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

MeasuresΒ how much money you payΒ for each share forΒ every €1 in earnings Takeda generates.

  • Above 15 is considered overpriced butΒ always compareΒ Takeda to theΒ Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of 68.75 means the investor is paying €68.75Β for every €1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Takeda Pharmaceutical Company Limited:

  • The EOD is 71.522. Based on the earnings, the company is expensive. -2
  • The MRQ is 68.745. Based on the earnings, the company is expensive. -2
  • The TTM is -113.242. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD71.522MRQ68.745+2.776
MRQ68.745TTM-113.242+181.987
TTM-113.242YOY0.240-113.481
TTM-113.2425Y56.713-169.954
5Y56.71310Y166.294-109.582
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Takeda Pharmaceutical Company Limited:

  • The EOD is 5.201. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The MRQ is 5.000. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The TTM is 17.675. Based on how much money comes from the company's main activities, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD5.201MRQ5.000+0.202
MRQ5.000TTM17.675-12.676
TTM17.675YOY3.858+13.817
TTM17.6755Y3.857+13.818
5Y3.85710Y2.338+1.520
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofΒ Takeda is to cheap or to expensiveΒ compared to its book value.

  • At or below 1 is considered healthyΒ (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A PB ratio of 0.88 means the investor is paying €0.88Β for each €1 in book value.

Let's take a look of the Price to Book Ratio trends of Takeda Pharmaceutical Company Limited:

  • The EOD is 0.917. Based on the equity, the company is cheap. +2
  • The MRQ is 0.882. Based on the equity, the company is cheap. +2
  • The TTM is 0.902. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD0.917MRQ0.882+0.036
MRQ0.882TTM0.902-0.020
TTM0.902YOY1.090-0.189
TTM0.9025Y1.232-0.331
5Y1.23210Y108.626-107.394
4.6.2. Total Gains per Share

2.4. Latest News of Takeda Pharmaceutical Company Limited

Does Takeda Pharmaceutical Company Limited still have the same value as the quarterly reports suggest? Recent changes may be an indication that the value of the company is changing. Read the news from Takeda Pharmaceutical Company Limited to keep up to date. Note: the news is often already included in the price.

DateTitleRead
2025-06-01
14:00
Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia VeraRead
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2023-12-312024-03-312024-06-302024-09-302024-12-31
Operating Income  328,008252,852580,860417,108997,968643,8601,641,828-1,776,516-134,688



6.2. Latest Balance Sheet

Balance Sheet of 2024-12-31. Currency in JPY. All numbers in thousands.

Summary
Total Assets15,106,844,000
Total Liabilities7,687,653,000
Total Stockholder Equity7,418,274,000
 As reported
Total Liabilities 7,687,653,000
Total Stockholder Equity+ 7,418,274,000
Total Assets = 15,106,844,000

Assets

Total Assets15,106,844,000
Total Current Assets2,754,287,000
Long-term Assets12,352,555,000
Total Current Assets
Cash And Cash Equivalents 494,126,000
Short-term Investments 32,621,000
Net Receivables 711,418,000
Inventory 1,246,427,000
Other Current Assets 179,259,000
Total Current Assets  (as reported)2,754,287,000
Total Current Assets  (calculated)2,663,851,000
+/- 90,436,000
Long-term Assets
Property Plant Equipment 2,017,776,000
Goodwill 5,522,112,000
Long Term Investments 410,206,000
Intangible Assets 3,952,039,000
Long-term Assets Other 74,158,000
Long-term Assets  (as reported)12,352,555,000
Long-term Assets  (calculated)11,976,291,000
+/- 376,264,000

Liabilities & Shareholders' Equity

Total Current Liabilities2,097,964,000
Long-term Liabilities5,589,689,000
Total Stockholder Equity7,418,274,000
Total Current Liabilities
Short Long Term Debt 135,467,000
Accounts payable 460,181,000
Other Current Liabilities 781,463,000
Total Current Liabilities  (as reported)2,097,964,000
Total Current Liabilities  (calculated)1,377,111,000
+/- 720,853,000
Long-term Liabilities
Long term Debt 4,704,681,000
Long-term Liabilities Other 678,090,000
Long-term Liabilities  (as reported)5,589,689,000
Long-term Liabilities  (calculated)5,382,771,000
+/- 206,918,000
Total Stockholder Equity
Retained Earnings 1,290,948,000
Total Stockholder Equity (as reported)7,418,274,000
Total Stockholder Equity (calculated)1,290,948,000
+/- 6,127,326,000
Other
Capital Stock1,694,660,000
Common Stock Shares Outstanding 1,585,179
Net Debt 4,346,022,000
Net Invested Capital 12,258,422,000
Net Working Capital 656,323,000



6.3. Balance Sheets Structured

Currency in JPY. All numbers in thousands.

 Trend2024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-31
> Total Assets 
4,142,032,000
4,355,782,000
4,345,922,000
4,375,955,000
4,410,558,000
4,106,463,000
4,159,577,000
4,274,839,000
5,767,223,000
13,872,322,000
13,550,424,000
12,880,141,000
13,031,494,000
12,821,094,000
12,613,852,000
12,414,747,000
12,286,137,000
12,912,293,000
12,657,234,000
12,560,273,000
12,698,519,000
13,178,018,000
14,065,426,000
14,588,847,000
13,504,705,000
13,957,750,000
14,792,738,000
14,871,889,000
14,222,947,000
15,108,792,000
16,227,683,000
14,573,000,000
15,106,844,000
15,106,844,00014,573,000,00016,227,683,00015,108,792,00014,222,947,00014,871,889,00014,792,738,00013,957,750,00013,504,705,00014,588,847,00014,065,426,00013,178,018,00012,698,519,00012,560,273,00012,657,234,00012,912,293,00012,286,137,00012,414,747,00012,613,852,00012,821,094,00013,031,494,00012,880,141,00013,550,424,00013,872,322,0005,767,223,0004,274,839,0004,159,577,0004,106,463,0004,410,558,0004,375,955,0004,345,922,0004,355,782,0004,142,032,000
   > Total Current Assets 
1,656,260,000
1,260,662,000
1,270,818,000
1,221,996,000
1,265,978,000
1,078,808,000
1,043,548,000
1,107,943,000
2,670,072,000
3,050,658,000
2,932,156,000
2,374,440,000
2,520,325,000
2,469,432,000
2,474,763,000
2,585,136,000
2,616,598,000
2,712,893,000
2,476,458,000
2,456,353,000
2,477,893,000
2,593,642,000
2,549,515,000
2,745,616,000
2,595,946,000
2,397,956,000
2,472,017,000
2,462,066,000
2,428,830,000
2,558,580,000
3,107,532,000
3,054,013,000
2,754,287,000
2,754,287,0003,054,013,0003,107,532,0002,558,580,0002,428,830,0002,462,066,0002,472,017,0002,397,956,0002,595,946,0002,745,616,0002,549,515,0002,593,642,0002,477,893,0002,456,353,0002,476,458,0002,712,893,0002,616,598,0002,585,136,0002,474,763,0002,469,432,0002,520,325,0002,374,440,0002,932,156,0003,050,658,0002,670,072,0001,107,943,0001,043,548,0001,078,808,0001,265,978,0001,221,996,0001,270,818,0001,260,662,0001,656,260,000
       Cash And Cash Equivalents 
559,166,000
319,455,000
432,302,000
430,895,000
440,253,000
294,522,000
231,480,000
317,080,000
297,873,000
702,093,000
593,745,000
543,517,000
568,279,000
637,614,000
589,787,000
630,868,000
617,635,000
966,222,000
654,920,000
607,881,000
724,341,000
849,695,000
645,991,000
798,137,000
685,141,000
533,530,000
316,380,000
318,051,000
288,359,000
457,800,000
804,272,000
859,015,000
494,126,000
494,126,000859,015,000804,272,000457,800,000288,359,000318,051,000316,380,000533,530,000685,141,000798,137,000645,991,000849,695,000724,341,000607,881,000654,920,000966,222,000617,635,000630,868,000589,787,000637,614,000568,279,000543,517,000593,745,000702,093,000297,873,000317,080,000231,480,000294,522,000440,253,000430,895,000432,302,000319,455,000559,166,000
       Short-term Investments 
0
56,683,000
0
0
26,227,000
80,646,000
19,147,000
0
12,412,000
23,276,000
21,342,000
13,916,000
20,144,000
15,822,000
11,138,000
15,314,000
36,664,000
36,598,000
29,930,000
25,742,000
27,555,000
25,305,000
18,543,000
31,932,000
41,467,000
20,174,000
52,229,000
15,756,000
29,045,000
15,089,000
53,386,000
47,200,000
32,621,000
32,621,00047,200,00053,386,00015,089,00029,045,00015,756,00052,229,00020,174,00041,467,00031,932,00018,543,00025,305,00027,555,00025,742,00029,930,00036,598,00036,664,00015,314,00011,138,00015,822,00020,144,00013,916,00021,342,00023,276,00012,412,000019,147,00080,646,00026,227,0000056,683,0000
       Net Receivables 
496,864,000
444,778,000
471,163,000
470,857,000
518,685,000
428,792,000
459,715,000
468,919,000
515,791,000
660,999,000
760,144,000
779,431,000
852,128,000
784,921,000
815,271,000
769,806,000
828,942,000
812,714,000
858,957,000
887,295,000
756,117,000
724,377,000
794,092,000
800,536,000
779,872,000
649,429,000
792,895,000
788,066,000
716,230,000
718,675,000
755,425,000
700,537,000
711,418,000
711,418,000700,537,000755,425,000718,675,000716,230,000788,066,000792,895,000649,429,000779,872,000800,536,000794,092,000724,377,000756,117,000887,295,000858,957,000812,714,000828,942,000769,806,000815,271,000784,921,000852,128,000779,431,000760,144,000660,999,000515,791,000468,919,000459,715,000428,792,000518,685,000470,857,000471,163,000444,778,000496,864,000
       Inventory 
222,910,000
226,294,000
234,679,000
234,300,000
225,101,000
212,944,000
221,424,000
233,304,000
223,398,000
986,744,000
902,522,000
840,840,000
801,341,000
759,599,000
759,378,000
743,482,000
739,352,000
753,881,000
779,148,000
783,476,000
811,324,000
853,167,000
927,511,000
953,450,000
927,286,000
986,457,000
1,083,374,000
1,155,866,000
1,169,640,000
1,209,869,000
1,276,739,000
1,206,431,000
1,246,427,000
1,246,427,0001,206,431,0001,276,739,0001,209,869,0001,169,640,0001,155,866,0001,083,374,000986,457,000927,286,000953,450,000927,511,000853,167,000811,324,000783,476,000779,148,000753,881,000739,352,000743,482,000759,378,000759,599,000801,341,000840,840,000902,522,000986,744,000223,398,000233,304,000221,424,000212,944,000225,101,000234,300,000234,679,000226,294,000222,910,000
       Other Current Assets 
377,320,000
213,452,000
132,674,000
85,944,000
81,939,000
61,904,000
111,782,000
88,640,000
1,620,598,000
109,666,000
108,093,000
104,697,000
278,433,000
271,476,000
299,189,000
425,666,000
394,005,000
143,478,000
183,433,000
177,701,000
186,111,000
166,403,000
181,921,000
193,493,000
203,647,000
196,276,000
179,883,000
200,083,000
179,394,000
168,875,000
197,009,000
161,205,000
179,259,000
179,259,000161,205,000197,009,000168,875,000179,394,000200,083,000179,883,000196,276,000203,647,000193,493,000181,921,000166,403,000186,111,000177,701,000183,433,000143,478,000394,005,000425,666,000299,189,000271,476,000278,433,000104,697,000108,093,000109,666,0001,620,598,00088,640,000111,782,00061,904,00081,939,00085,944,000132,674,000213,452,000377,320,000
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
10,821,664,000
10,618,268,000
10,505,701,000
10,511,169,000
10,351,662,000
10,139,089,000
9,829,611,000
9,669,539,000
10,199,400,000
10,180,777,000
10,103,920,000
10,220,627,000
10,584,376,000
11,515,910,000
11,843,231,000
10,908,758,000
11,559,794,000
12,320,721,000
12,409,821,000
11,794,118,000
12,550,214,000
13,120,150,000
11,518,986,000
12,352,555,000
12,352,555,00011,518,986,00013,120,150,00012,550,214,00011,794,118,00012,409,821,00012,320,721,00011,559,794,00010,908,758,00011,843,231,00011,515,910,00010,584,376,00010,220,627,00010,103,920,00010,180,777,00010,199,400,0009,669,539,0009,829,611,00010,139,089,00010,351,662,00010,511,169,00010,505,701,00010,618,268,00010,821,664,000000000000
       Property Plant Equipment 
523,314,000
530,152,000
532,337,000
541,209,000
541,688,000
536,801,000
528,155,000
533,088,000
601,774,000
1,316,531,000
1,481,113,000
1,457,060,000
1,468,842,000
1,386,370,000
1,366,177,000
1,366,950,000
1,363,141,000
1,453,917,000
1,452,172,000
1,459,919,000
1,493,587,000
1,582,800,000
1,705,367,000
1,760,327,000
1,656,416,000
1,691,229,000
1,795,315,000
1,894,136,000
1,841,499,000
1,989,777,000
2,085,382,000
1,887,620,000
2,017,776,000
2,017,776,0001,887,620,0002,085,382,0001,989,777,0001,841,499,0001,894,136,0001,795,315,0001,691,229,0001,656,416,0001,760,327,0001,705,367,0001,582,800,0001,493,587,0001,459,919,0001,452,172,0001,453,917,0001,363,141,0001,366,950,0001,366,177,0001,386,370,0001,468,842,0001,457,060,0001,481,113,0001,316,531,000601,774,000533,088,000528,155,000536,801,000541,688,000541,209,000532,337,000530,152,000523,314,000
       Goodwill 
777,344,000
1,022,711,000
1,052,983,000
1,072,962,000
1,078,236,000
1,029,248,000
1,053,998,000
1,085,706,000
1,053,506,000
4,161,403,000
4,064,572,000
4,029,507,000
4,104,150,000
4,012,528,000
3,984,271,000
3,856,147,000
3,824,804,000
4,033,917,000
4,058,935,000
4,078,369,000
4,167,993,000
4,407,749,000
4,813,610,000
4,994,632,000
4,690,949,000
4,790,723,000
5,182,128,000
5,301,017,000
5,111,287,000
5,410,067,000
5,733,710,000
5,160,112,000
5,522,112,000
5,522,112,0005,160,112,0005,733,710,0005,410,067,0005,111,287,0005,301,017,0005,182,128,0004,790,723,0004,690,949,0004,994,632,0004,813,610,0004,407,749,0004,167,993,0004,078,369,0004,058,935,0004,033,917,0003,824,804,0003,856,147,0003,984,271,0004,012,528,0004,104,150,0004,029,507,0004,064,572,0004,161,403,0001,053,506,0001,085,706,0001,053,998,0001,029,248,0001,078,236,0001,072,962,0001,052,983,0001,022,711,000777,344,000
       Long Term Investments 
344,931,000
303,047,000
352,815,000
365,920,000
371,473,000
304,385,000
331,069,000
426,906,000
282,855,000
306,899,000
308,937,000
350,578,000
394,532,000
369,455,000
336,638,000
349,602,000
376,051,000
348,350,000
374,659,000
352,091,000
334,812,000
330,133,000
381,607,000
425,766,000
369,469,000
378,857,000
393,529,000
416,364,000
372,918,000
430,608,000
447,181,000
277,314,000
410,206,000
410,206,000277,314,000447,181,000430,608,000372,918,000416,364,000393,529,000378,857,000369,469,000425,766,000381,607,000330,133,000334,812,000352,091,000374,659,000348,350,000376,051,000349,602,000336,638,000369,455,000394,532,000350,578,000308,937,000306,899,000282,855,000426,906,000331,069,000304,385,000371,473,000365,920,000352,815,000303,047,000344,931,000
       Intangible Assets 
684,861,000
1,065,835,000
1,055,752,000
1,092,637,000
1,073,469,000
1,014,264,000
1,057,985,000
1,067,172,000
1,020,216,000
4,860,368,000
4,580,341,000
4,425,199,000
4,308,394,000
4,171,361,000
4,043,156,000
3,878,257,000
3,756,723,000
3,909,106,000
3,856,432,000
3,783,677,000
3,791,875,000
3,818,544,000
4,145,090,000
4,187,055,000
3,765,757,000
4,269,657,000
4,514,084,000
4,402,421,000
4,097,022,000
4,274,683,000
4,366,147,000
3,770,620,000
3,952,039,000
3,952,039,0003,770,620,0004,366,147,0004,274,683,0004,097,022,0004,402,421,0004,514,084,0004,269,657,0003,765,757,0004,187,055,0004,145,090,0003,818,544,0003,791,875,0003,783,677,0003,856,432,0003,909,106,0003,756,723,0003,878,257,0004,043,156,0004,171,361,0004,308,394,0004,425,199,0004,580,341,0004,860,368,0001,020,216,0001,067,172,0001,057,985,0001,014,264,0001,073,469,0001,092,637,0001,055,752,0001,065,835,000684,861,000
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
87,472,000
94,213,000
92,449,000
87,242,000
103,846,000
103,021,000
100,226,000
96,568,000
100,341,000
95,022,000
94,289,000
79,645,000
82,611,000
84,677,000
80,699,000
66,774,000
63,325,000
60,143,000
59,672,000
54,703,000
51,214,000
106,098,000
85,016,000
74,158,000
74,158,00085,016,000106,098,00051,214,00054,703,00059,672,00060,143,00063,325,00066,774,00080,699,00084,677,00082,611,00079,645,00094,289,00095,022,000100,341,00096,568,000100,226,000103,021,000103,846,00087,242,00092,449,00094,213,00087,472,000000000000
> Total Liabilities 
2,097,623,000
2,406,817,000
2,309,139,000
2,270,258,000
2,276,475,000
2,089,054,000
2,093,003,000
2,102,678,000
3,724,645,000
8,708,734,000
8,675,973,000
8,010,457,000
8,155,275,000
8,093,608,000
7,923,088,000
7,748,248,000
7,646,709,000
7,735,116,000
7,357,075,000
7,235,912,000
7,366,696,000
7,494,495,000
7,748,043,000
7,875,358,000
7,328,207,000
7,603,079,000
7,871,069,000
7,800,864,000
7,480,340,000
7,834,787,000
8,428,451,000
7,651,403,000
7,687,653,000
7,687,653,0007,651,403,0008,428,451,0007,834,787,0007,480,340,0007,800,864,0007,871,069,0007,603,079,0007,328,207,0007,875,358,0007,748,043,0007,494,495,0007,366,696,0007,235,912,0007,357,075,0007,735,116,0007,646,709,0007,748,248,0007,923,088,0008,093,608,0008,155,275,0008,010,457,0008,675,973,0008,708,734,0003,724,645,0002,102,678,0002,093,003,0002,089,054,0002,276,475,0002,270,258,0002,309,139,0002,406,817,0002,097,623,000
   > Total Current Liabilities 
931,770,000
1,366,091,000
939,013,000
838,769,000
878,170,000
737,509,000
733,444,000
844,192,000
871,707,000
2,510,931,000
2,006,623,000
1,634,634,000
2,127,365,000
2,175,898,000
2,031,544,000
1,709,661,000
1,804,958,000
1,773,176,000
1,706,782,000
1,918,750,000
1,809,254,000
2,145,730,000
2,166,942,000
2,391,720,000
2,236,809,000
2,481,940,000
2,501,741,000
2,367,617,000
2,282,168,000
2,313,103,000
2,465,202,000
2,387,237,000
2,097,964,000
2,097,964,0002,387,237,0002,465,202,0002,313,103,0002,282,168,0002,367,617,0002,501,741,0002,481,940,0002,236,809,0002,391,720,0002,166,942,0002,145,730,0001,809,254,0001,918,750,0001,706,782,0001,773,176,0001,804,958,0001,709,661,0002,031,544,0002,175,898,0002,127,365,0001,634,634,0002,006,623,0002,510,931,000871,707,000844,192,000733,444,000737,509,000878,170,000838,769,000939,013,0001,366,091,000931,770,000
       Short-term Debt 
975,899,000
1,203,701,000
1,144,847,000
1,137,358,000
140,000,000
1,038,811,000
994,971,000
120,913,000
120,743,000
984,946,000
520,665,000
171,391,000
611,701,000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000611,701,000171,391,000520,665,000984,946,000120,743,000120,913,000994,971,0001,038,811,000140,000,0001,137,358,0001,144,847,0001,203,701,000975,899,000
       Short Long Term Debt 
975,899,000
1,203,701,000
1,144,847,000
1,137,358,000
140,000,000
1,038,811,000
994,971,000
120,913,000
120,743,000
984,946,000
520,665,000
171,391,000
611,701,000
586,817,000
580,732,000
276,616,000
284,474,000
22,153,000
24,272,000
214,886,000
122,936,000
203,993,000
281,897,000
568,228,000
372,019,000
339,600,000
416,860,000
274,841,000
370,292,000
367,251,000
438,743,000
624,101,000
135,467,000
135,467,000624,101,000438,743,000367,251,000370,292,000274,841,000416,860,000339,600,000372,019,000568,228,000281,897,000203,993,000122,936,000214,886,00024,272,00022,153,000284,474,000276,616,000580,732,000586,817,000611,701,000171,391,000520,665,000984,946,000120,743,000120,913,000994,971,0001,038,811,000140,000,0001,137,358,0001,144,847,0001,203,701,000975,899,000
       Accounts payable 
231,832,000
125,713,000
219,633,000
209,677,000
223,452,000
133,705,000
225,492,000
225,752,000
248,616,000
212,348,000
278,886,000
280,409,000
299,892,000
211,627,000
289,741,000
272,778,000
326,978,000
232,105,000
320,645,000
336,600,000
351,185,000
295,934,000
424,358,000
388,616,000
381,109,000
649,233,000
440,924,000
421,078,000
483,666,000
319,955,000
468,882,000
413,335,000
460,181,000
460,181,000413,335,000468,882,000319,955,000483,666,000421,078,000440,924,000649,233,000381,109,000388,616,000424,358,000295,934,000351,185,000336,600,000320,645,000232,105,000326,978,000272,778,000289,741,000211,627,000299,892,000280,409,000278,886,000212,348,000248,616,000225,752,000225,492,000133,705,000223,452,000209,677,000219,633,000125,713,000231,832,000
       Other Current Liabilities 
464,094,000
693,239,000
515,745,000
489,103,000
514,718,000
601,659,000
506,767,000
497,527,000
502,348,000
686,373,000
725,300,000
578,502,000
1,215,772,000
1,336,370,000
1,161,071,000
1,160,267,000
1,193,506,000
1,468,731,000
1,361,865,000
1,367,264,000
1,335,133,000
1,591,926,000
1,460,687,000
1,434,876,000
1,483,681,000
1,493,107,000
873,428,000
1,671,698,000
833,297,000
764,005,000
830,252,000
701,349,000
781,463,000
781,463,000701,349,000830,252,000764,005,000833,297,0001,671,698,000873,428,0001,493,107,0001,483,681,0001,434,876,0001,460,687,0001,591,926,0001,335,133,0001,367,264,0001,361,865,0001,468,731,0001,193,506,0001,160,267,0001,161,071,0001,336,370,0001,215,772,000578,502,000725,300,000686,373,000502,348,000497,527,000506,767,000601,659,000514,718,000489,103,000515,745,000693,239,000464,094,000
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
6,197,803,000
6,669,350,000
6,375,823,000
6,027,910,000
5,917,710,000
5,891,544,000
6,038,587,000
5,841,751,000
5,961,940,000
5,712,309,000
5,317,162,000
5,557,442,000
5,348,765,000
5,581,101,000
5,483,638,000
5,091,398,000
5,121,139,000
5,369,328,000
5,433,247,000
5,198,172,000
5,521,684,000
5,963,249,000
5,264,166,000
5,589,689,000
5,589,689,0005,264,166,0005,963,249,0005,521,684,0005,198,172,0005,433,247,0005,369,328,0005,121,139,0005,091,398,0005,483,638,0005,581,101,0005,348,765,0005,557,442,0005,317,162,0005,712,309,0005,961,940,0005,841,751,0006,038,587,0005,891,544,0005,917,710,0006,027,910,0006,375,823,0006,669,350,0006,197,803,000000000000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
310,960,000
480,500,000
470,962,000
469,349,000
451,922,000
460,009,000
524,324,000
543,734,000
574,575,000
555,314,000
523,732,000
532,177,000
536,156,000
581,681,000
618,646,000
570,244,000
599,657,000
568,106,000
646,229,000
614,599,000
768,770,000
704,122,000
639,310,000
678,090,000
678,090,000639,310,000704,122,000768,770,000614,599,000646,229,000568,106,000599,657,000570,244,000618,646,000581,681,000536,156,000532,177,000523,732,000555,314,000574,575,000543,734,000524,324,000460,009,000451,922,000469,349,000470,962,000480,500,000310,960,000000000000
> Total Stockholder Equity
1,981,581,000
1,894,261,000
2,014,570,000
2,085,734,000
2,113,885,000
1,997,424,000
2,043,500,000
2,168,358,000
2,038,682,000
5,159,582,000
4,870,365,000
4,865,714,000
4,872,072,000
4,723,483,000
4,686,763,000
4,662,402,000
4,635,353,000
5,173,037,000
5,299,774,000
5,323,935,000
5,331,330,000
5,683,019,000
6,316,832,000
6,712,929,000
6,175,978,000
6,354,122,000
6,921,052,000
7,070,352,000
6,741,934,000
7,273,264,000
7,798,417,000
6,920,754,000
7,418,274,000
7,418,274,0006,920,754,0007,798,417,0007,273,264,0006,741,934,0007,070,352,0006,921,052,0006,354,122,0006,175,978,0006,712,929,0006,316,832,0005,683,019,0005,331,330,0005,323,935,0005,299,774,0005,173,037,0004,635,353,0004,662,402,0004,686,763,0004,723,483,0004,872,072,0004,865,714,0004,870,365,0005,159,582,0002,038,682,0002,168,358,0002,043,500,0001,997,424,0002,113,885,0002,085,734,0002,014,570,0001,894,261,0001,981,581,000
   Common Stock
64,988,000
65,203,000
65,714,000
65,957,000
66,233,000
77,914,000
77,923,000
77,942,000
77,942,000
1,643,585,000
1,668,092,000
1,668,092,000
1,668,092,000
1,668,123,000
1,668,145,000
1,668,145,000
1,668,145,000
1,668,145,000
1,669,125,000
1,676,263,000
1,676,263,000
1,676,263,000
1,676,277,000
1,676,330,000
1,676,334,000
0
0
1,676,503,000
0
0
0
0
0
000001,676,503,000001,676,334,0001,676,330,0001,676,277,0001,676,263,0001,676,263,0001,676,263,0001,669,125,0001,668,145,0001,668,145,0001,668,145,0001,668,145,0001,668,123,0001,668,092,0001,668,092,0001,668,092,0001,643,585,00077,942,00077,942,00077,923,00077,914,00066,233,00065,957,00065,714,00065,203,00064,988,000
   Retained Earnings 
1,546,995,000
1,511,817,000
1,586,328,000
1,614,365,000
1,609,841,000
1,557,307,000
1,593,297,000
1,648,094,000
1,614,904,000
1,569,365,000
1,405,026,000
1,477,589,000
1,378,447,000
1,369,972,000
1,330,054,000
1,337,065,000
1,306,568,000
1,509,906,000
1,503,811,000
1,551,150,000
1,466,926,000
1,479,716,000
1,459,764,000
1,530,200,000
1,507,720,000
1,541,146,000
1,490,097,000
1,446,018,000
1,396,838,000
1,391,203,000
1,338,192,000
1,431,684,000
1,290,948,000
1,290,948,0001,431,684,0001,338,192,0001,391,203,0001,396,838,0001,446,018,0001,490,097,0001,541,146,0001,507,720,0001,530,200,0001,459,764,0001,479,716,0001,466,926,0001,551,150,0001,503,811,0001,509,906,0001,306,568,0001,337,065,0001,330,054,0001,369,972,0001,378,447,0001,477,589,0001,405,026,0001,569,365,0001,614,904,0001,648,094,0001,593,297,0001,557,307,0001,609,841,0001,614,365,0001,586,328,0001,511,817,0001,546,995,000
   Capital Surplus 000000000000000000000000000000000
   Treasury Stock000000000000000000000000000000000
   Other Stockholders Equity 
348,707,000
291,003,000
350,337,000
387,442,000
414,564,000
345,836,000
352,725,000
417,712,000
315,875,000
353,542,000
224,037,000
140,974,000
239,284,000
92,564,000
87,807,000
47,885,000
41,551,000
366,114,000
425,162,000
451,066,000
581,592,000
934,174,000
1,602,639,000
1,911,168,000
1,380,202,000
0
0
2,287,968,000
0
0
0
0
0
000002,287,968,000001,380,202,0001,911,168,0001,602,639,000934,174,000581,592,000451,066,000425,162,000366,114,00041,551,00047,885,00087,807,00092,564,000239,284,000140,974,000224,037,000353,542,000315,875,000417,712,000352,725,000345,836,000414,564,000387,442,000350,337,000291,003,000348,707,000



6.4. Balance Sheets

Currency in JPY. All numbers in thousands.




6.5. Cash Flows

Currency in JPY. All numbers in thousands.




6.6. Income Statements

Currency in JPY. All numbers in thousands.


6.7. Latest Income Statement

Income Statement (annual), 2024-03-31. Currency in JPY. All numbers in thousands.

Gross Profit (+$)
totalRevenue4,263,762,000
Cost of Revenue-1,426,678,000
Gross Profit2,837,084,0002,837,084,000
 
Operating Income (+$)
Gross Profit2,837,084,000
Operating Expense-3,942,809,000
Operating Income320,953,000-1,105,725,000
 
Operating Expense (+$)
Research Development729,924,000
Selling General Administrative1,053,819,000
Selling And Marketing Expenses-
Operating Expense3,942,809,0001,783,743,000
 
Net Interest Income (+$)
Interest Income11,293,000
Interest Expense-119,535,000
Other Finance Cost-32,221,000
Net Interest Income-140,463,000
 
Pretax Income (+$)
Operating Income320,953,000
Net Interest Income-140,463,000
Other Non-Operating Income Expenses-
Income Before Tax (EBT)52,791,000448,650,000
EBIT - interestExpense = -119,535,000
144,067,000
263,602,000
Interest Expense119,535,000
Earnings Before Interest and Taxes (EBIT)-172,326,000
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax52,791,000
Tax Provision--91,406,000
Net Income From Continuing Ops144,197,000144,197,000
Net Income144,067,000
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net-127,697,000140,463,000
 

Technical Analysis of Takeda
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Takeda. The general trend of Takeda is UNKNOWN with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Takeda's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator StateBullish trend Bearish trend
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Takeda Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

SupportΒ is a price level at which demand for an asset is strong enough to prevent the price from falling further.
ResistanceΒ is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Takeda Pharmaceutical Company Limited.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 26.28 < 26.45 < 27.12.

The bearish price targets are: 24.10 > 24.09 > 23.99.

Know someone who trades $TKD? Share this with them.πŸ‘‡

Takeda Pharmaceutical Company Limited Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows theΒ moving averageΒ of the selected period.

  • Moving averages are laggingΒ trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Takeda Pharmaceutical Company Limited. The current mas is .

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Takeda Pharmaceutical Company Limited Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows theΒ momentumΒ of theΒ selected period based on two moving averages.

  • MACD is aΒ lagging momentumΒ indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Takeda Pharmaceutical Company Limited.

Takeda Pharmaceutical Company Limited Daily Moving Average Convergence/Divergence (MACD) ChartTakeda Pharmaceutical Company Limited Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Takeda Pharmaceutical Company Limited. The current adx is .

Takeda Pharmaceutical Company Limited Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • ShowsΒ the current trend.
  • ShowsΒ potential entry signals.
  • ShowsΒ Β potential exit signals.
  • Can be used to placeΒ trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Takeda Pharmaceutical Company Limited.

Takeda Pharmaceutical Company Limited Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentumΒ indicator, meaning the signals are instant.
  • RangesΒ between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Takeda Pharmaceutical Company Limited.

Takeda Pharmaceutical Company Limited Daily Relative Strength Index (RSI) ChartTakeda Pharmaceutical Company Limited Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

ComparesΒ a certain price to multiple prices ranging over time.

  • LeadingΒ momentumΒ indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • RangesΒ between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Takeda Pharmaceutical Company Limited.

Takeda Pharmaceutical Company Limited Daily Stochastic Oscillator ChartTakeda Pharmaceutical Company Limited Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,Β the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Takeda Pharmaceutical Company Limited.

Takeda Pharmaceutical Company Limited Daily Commodity Channel Index (CCI) ChartTakeda Pharmaceutical Company Limited Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Takeda Pharmaceutical Company Limited.

Takeda Pharmaceutical Company Limited Daily Chande Momentum Oscillator (CMO) ChartTakeda Pharmaceutical Company Limited Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

Β Shows the current price relative to the highest high over the last 14 days.
Β 

  • Lagging momentum indicator
  • Ranging between 0 andΒ -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Takeda Pharmaceutical Company Limited.

Takeda Pharmaceutical Company Limited Daily Williams %R ChartTakeda Pharmaceutical Company Limited Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversoldΒ 

Score

Let's take a look at the Bollinger Bands of Takeda Pharmaceutical Company Limited.

Takeda Pharmaceutical Company Limited Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Takeda Pharmaceutical Company Limited.

Takeda Pharmaceutical Company Limited Daily Average True Range (ATR) ChartTakeda Pharmaceutical Company Limited Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Β Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Takeda Pharmaceutical Company Limited.

Takeda Pharmaceutical Company Limited Daily On-Balance Volume (OBV) ChartTakeda Pharmaceutical Company Limited Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Takeda Pharmaceutical Company Limited.

Takeda Pharmaceutical Company Limited Daily Money Flow Index (MFI) ChartTakeda Pharmaceutical Company Limited Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Takeda Pharmaceutical Company Limited.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-01-29 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-01-30 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-01-31 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-02-03 00:00:00WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-02-04 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-05 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-06 00:00:00CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-07 00:00:00MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-02-11 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-02-12 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-02-13 00:00:00CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-02-14 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-02-17 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-18 00:00:00CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-02-19 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-02-24 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-02-25 00:00:00ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-27 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-03 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-04 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-05 00:00:00RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-07 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-10 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-11 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-13 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-14 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-17 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-03-18 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-19 00:00:00SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-20 00:00:00CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-03-21 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-03-24 00:00:00WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-03-25 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-26 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-03-27 00:00:00MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-03-28 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-03-31 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-01 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-03 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-04 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-07 00:00:00CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-08 00:00:00ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-10 00:00:00RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2025-04-11 00:00:00WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-04-14 00:00:00RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2025-04-15 00:00:00ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-17 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-22 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-04-23 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-04-24 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-28 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-05-05 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-05-06 00:00:00ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-05-07 00:00:00CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-08 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-05-09 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-05-12 00:00:00SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-05-13 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-05-15 00:00:00RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-20 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-21 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-22 00:00:00CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-23 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-26 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-05-27 00:00:00CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-28 00:00:00WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-05-29 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-30 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-03 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-05 00:00:00CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-06 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-06-09 00:00:00SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-06-10 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-16 00:00:00CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-18 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.

6.3. Candlestick Patterns

Takeda Pharmaceutical Company Limited Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Takeda Pharmaceutical Company Limited based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose25.760
Total0/1 (0.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Takeda with someone you think should read this too:
  • Are you bullish or bearish on Takeda? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Takeda? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Takeda Pharmaceutical Company Limited

I send you an email if I find something interesting about Takeda Pharmaceutical Company Limited.


Comments

How you think about this?

Leave a comment

Stay informed about Takeda Pharmaceutical Company Limited.

Receive notifications about Takeda Pharmaceutical Company Limited in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.